MCL1 and melanoma: 3.2. Levels of MCL-1 and Its Endogenous Inhibitors, BIM and NOXA, Are Modulated in Trametinib-Resistant Melanoma Cells during Alternating Periods of Trametinib Withdrawal and Rechallenge